News

Boundless Bio to Present Breakthrough Cancer Research at AACR

Boundless Bio to Present Breakthrough Cancer Research at AACR

Exciting Presentation at an Esteemed Conference

Boundless Bio, a dedicated force in the oncology sector, is set to make a significant impact at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This prominent event will occur in Boston, showcasing cutting-edge research in cancer treatment strategies, and will run from October 22 to 26, 2025.

Innovative Research on ecDNA

At the heart of Boundless Bio's mission is an investigation into extrachromosomal DNA (ecDNA) and its role in cancer. This clinical-stage biotech firm aims to address the crucial needs of patients suffering from oncogene amplified tumors. With a commitment to unveiling effective treatments, Boundless Bio's research is paving the way for novel therapies that seek to alter the course of cancer care.

Details of the Presentation

During the conference, Boundless Bio will present vital findings through a poster session titled: "Synergistic oral combination of selective RNR inhibitor BBI-825 with selective CHK1 inhibitor BBI-355 targets unique dependencies of oncogene amplified cancers." Set for October 23, 2025, from 12:30 PM to 4:00 PM ET, this poster session promises to share crucial insights into their ongoing research.

What Makes This Research Stand Out?

This presentation will delve into the mood of combining two potent inhibitors: BBI-825, which selectively targets ribonucleotide reductase (RNR), and BBI-355, which focuses on checkpoint kinase 1 (CHK1). Together, these therapies are positioned to target unique dependencies found in oncogene amplified cancers, potentially revolutionizing treatment options available to patients.

About Boundless Bio

Headquartered in San Diego, Boundless Bio is relentlessly pursuing advancements in cancer therapy. Their research encompasses the development of ecDNA-directed therapeutic candidates, including BBI-355 and BBI-825, both in clinical trials. The company is also investigating further potential treatments, such as BBI-940, a promising new candidate aimed at degrading Kinesin, a protein implicated in cell division and cancer progression.

Company Vision and Commitment

Boundless Bio's journey is marked by an unwavering commitment to advancing therapeutic paradigms for individuals facing challenging oncogene-amplified cancers. Their initiative signifies hope and innovative treatment solutions for patients previously deemed as having limited options.

Connecting with the Community

As Boundless Bio continues on its path to transform cancer therapies, staying connected with stakeholders and interested parties is crucial. The company encourages those who seek further information about their groundbreaking work to visit their official website and follow their progress on professional platforms like LinkedIn and X.

Investor and Media Relations

For inquiries related to investment or media opportunities, Boundless Bio has appointed dedicated professionals ready to engage with the community. Investors can reach out to James Lee via email, while media queries can be directed to Carly Scaduto, ensuring that all communications are handled with care and transparency.

Frequently Asked Questions

What is the focus of Boundless Bio's research?

Boundless Bio primarily focuses on extrachromosomal DNA (ecDNA) and its implications in oncogene amplified cancers, striving to develop innovative therapies.

When will the presentation at the AACR conference take place?

The presentation is scheduled for October 23, 2025, during the poster session that will run from 12:30 PM to 4:00 PM ET.

What therapies are being highlighted in the conference?

The highlighted therapies are BBI-825 and BBI-355, which work together to target specific dependencies of oncogene amplified cancers.

How can I learn more about Boundless Bio's initiatives?

You can learn more about Boundless Bio by visiting their official website and following their updates on professional social media platforms.

Who should I contact for investment-related queries?

Investor inquiries can be directed to James Lee at Boundless Bio for assistance with specific questions or discussions regarding their investor relations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

Lawsuit Filed for Newmont Corporation (NEM) Investors

Updated Category News Views 99

Understanding the Class Action Against Newmont Corporation In recent news, investors in Newmont Corporation (NEM) are urged to take notice of a class action securities lawsuit activated by Levi & Korsinsky, LLP. This legal endeavor aims to seek restitution for shareholders impacted by alleged fraudulent activities linked to the company’s operations. What is the Class...

Continue Reading
Plains All American Pipeline Unveils Q3 2024 Distributions

Updated Category News Views 48

Quarterly Distributions Announced by Plains All American Plains All American Pipeline, L.P. (NASDAQ: PAA) and Plains GP Holdings (NASDAQ: PAGP) have just shared their quarterly distributions for the third quarter of 2024, making this an important update for shareholders and investors alike. Details of the Quarterly Distribution The companies revealed a consistent approach...

Continue Reading
FLSmidth Achieves Record Profitability in 2024 Annual Summary

Updated Category News Views 667

FLSmidth 2024 Annual Report Highlights Major Achievements On February 20, 2025, FLSmidth’s Board of Directors approved the Annual Report for 2024, showcasing significant improvements in profitability and outlining the progress made towards key transformation efforts. Major Highlights from 2024 include: Increased Mining Service order intake by 2% from the previous year,...

Continue Reading
DAX Stumbles Slightly as Mixed Trends Shape German Stocks

Updated Category News Views 226

Exploring the Mixed Signals in the German Stock Market The German stock market concluded on a mixed note recently, reflecting a variety of performance trends among different sectors. While certain sectors saw positive movement, others faced declines, illustrating the complexity of the current economic environment. DAX Performance and Sector Shifts At the closing bell in...

Continue Reading
Ray Dalio's Insights on Tech Sector Growth Amid Deregulation

Updated Category News Views 327

Understanding Ray Dalio's Economic Perspective In a recent discussion, renowned investor Ray Dalio analyzed the shifting economic landscape under the upcoming presidential administration. He highlighted the potential changes that could significantly affect how tech companies operate in a less regulated environment. Potential Changes in the Regulatory Landscape Dalio's...

Continue Reading